Business Wire

CORRECTING and REPLACING GRAPHIC: Seoul Semiconductor’s SunLike Series Natural Spectrum LEDs Shown in a Recent Study to Have Beneficial Effects on Human Health and Well-being

Share

Please replace the graphic with the accompanying corrected graphic on the release issued May 27, 2019 at 9am BST.
The release reads:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190527005028/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Seoul Semiconductor's SunLike Series Natural Spectrum LEDs (Graphic: Business Wire)

SEOUL SEMICONDUCTOR’S SUNLIKE SERIES NATURAL SPECTRUM LEDS SHOWN IN A RECENT STUDY TO HAVE BENEFICIAL EFFECTS ON HUMAN HEALTH AND WELL-BEING

Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED products and technology, announced the results of a recent study conducted by Dr. Octavio L. Perez, adjunct researcher in Integrative Lighting at Mount Sinai Hospital in NYC, NY, USA on the non-visual melanopic stimulus of LED sources. The study showed that the company’s SunLike Series natural spectrum LEDs provide up to 21% more melanopic stimulus than conventional LEDs at 4000K, and the same melanopic stimulus as daylight at 6500K (D65).

In addition to the visual effects of light and lighting on people, such as visual acuity and color fidelity, there are also non-visual effects. These non-visual effects can affect human health and well-being in aspects related to sleep, awakeness, alertness, circadian rhythmicity, circadian disruption, performance, and mood. Recent building standards, such as the ‘WELL Building Standard,’ assess these non-visual effects of lighting in buildings in terms of the ‘melanopic stimulus,’ not just in terms of conventional photometry and colorimetry.

The recent study evaluated the M-EDI (CIE DIS S026/E:2018 Melanopic Equivalent Daylight Illuminance) of different light sources at different correlated color temperatures (CCT in K). M-EDI is the only metric compliant with the International System of Units (IS) to evaluate the non-visual stimulus of light and lighting, based on the CIE (the International Commission on Illumination) D65 standard daylight illuminant. The preliminary results indicate that the SunLike Series natural spectrum LEDs provide more melanopic stimulus, at any given CCT, than any other LED light source at the same photopic illuminance (in lux) – up to 21% more M-EDI stimulus compared to a conventional 4000K CRI80 LED (4000K being the prevalent CCT in office and school environments).

A typical 4000K CRI80 LED provides 59.30 M-EDI lux for every 100 photopic lux, and a 4000K SunLike LED provides 71.94 M-EDI lux at the same photopic illuminance level. At 6500K, the SunLike LED delivers 99.95% of the M-EDI melanopic stimulus provided by the CIE D65 daylight standard illuminant at the same photopic illuminance. It means that at 6500K, the SunLike Series LEDs provide the same natural melanopic stimulus as daylight (D65).

The reason for this is that the SunLike Series natural spectrum LEDs have a continuous spectral power distribution (SPD) emission that mimics sunlight spectrum at different CCT, in the visual region not including UV and IR. Conventional LED light sources have a peak at 450nm, followed by a valley at the peak of the melanopic efficiency curve, around 480nm. This peak at 450nm for conventional LEDs may also produce non-desired effects on eye health. The melanopic stimulus of the 6500K SunLike LEDs match the shape of the melanopic stimulus provided by D65, avoiding potential blue light peak and ethical issues.

Human centric lighting solutions go beyond the prevalent visual metrics of photometry colorimetry and conventional lighting design. The SunLike Series natural spectrum LEDs offer better visual appearance and color fidelity (CRI95+), and are specifically designed and engineered to provide more benefits and energy for human health and well-being than any other LED in the marketplace. SunLike Series LEDs are the light source of choice for integrative lighting solutions.

Seoul Semiconductor’s SunLike Series natural spectrum LEDs are the world’s first LEDs to produce light that closely matches the spectrum of natural sunlight. It has also achieved the highest level of eye safety certification from the International Commission on Illumination as an RG-1 level light source with no photo-biological risks.

SunLike Series natural spectrum LEDs were co-developed through the combination of Seoul Semiconductor’s optical semiconductor technology and Toshiba Materials’ TRI-R technology, which defines its original concept as “the light closest to the sun for human well-being.” TRI-R technology enables the spectrum of natural sunlight to be reproduced by a white LED light source. TRI-R is a registered trademark of Toshiba Material Co., Ltd.

The left figure is how the melanopic stimulus of commercial LEDs increases and the right figure shows the same results by family of LEDs. SunLike LEDs provide more melanopic stimulus than the other LEDs (study under publication).

# # #

About Dr. Octavio L. Perez
Dr. Octavio L. Perez is a passionate professional and scholar who contributes to exploring, developing and bringing to the real world the benefits of light and lighting for human wellbeing and wellness, and ultimately health, integrating in this vision the traditional visual and aesthetical principles of lighting, altogether with energy savings and sustainability values. He works internationally as an independent consultant, focused in human centric lighting (HCL), more precisely “affective lighting”. He is also an adjunct researcher at Mount Sinai Hospital in NYC, where he completed his doctoral research with funding from NIH (National Institutes of Health).

About Seoul Semiconductor
Seoul Semiconductor develops and commercializes LEDs for automotive, general illumination, specialty lighting, and backlighting markets. As the second-largest LED manufacturer globally excluding the captive market, Seoul Semiconductor holds more than 14,000 patents, offers a wide range of technologies, and mass produces innovative LED products such as SunLike – delivering the world’s best light quality in a next-generation LED enabling human-centric lighting optimized for circadian rhythms; WICOP – a simpler structured package-free LED which provides market leading color uniformity and cost savings at the fixture level, providing high lumen density and design flexibility; NanoDriver Series – the world’s smallest 24W DC LED drivers; Acrich, the world's first high-voltage AC-driven LED technology developed in 2005, including all AC LED-related technologies from chip to module and circuit fabrication, and nPola, a new LED product based on GaN-substrate technology that achieves more than ten times the output of conventional LEDs. UCD constitutes a high color gamut display which delivers more than 90% NTSC. For more information, please visit www.seoulsemicon.com/en.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Seoul Semiconductor Inc.
Jeonghee Kim
Tel: +82-70-4391-8311
Email: jeonghee.kim@seoulsemicon.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AB InBev Reports First Quarter 2025 Results8.5.2025 08:03:00 EEST | Press release

Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250507671244/en/ AB InBev Strategic Priorities Regulated information1 “Beer is a passion point for consumers. The strength of the beer category and the continued momentum of our megabrands delivered another quarter of profitable growth. EBITDA increased at the top-end of our outlook and the ongoing optimization of our business drove Underlying EPS growth of 7.1%. The consistent execution of our strategy by our teams and partners drove a solid start to the year and reinforces our confidence in delivering on our outlook for 2025.” – Michel Doukeris, CEO, AB InBev Revenue +1.5% Revenue increased by 1.5% with revenue per hl growth of 3.7%. Reported revenue decreased by 6.3% to 13 628 million USD, impacted by unfavorable currency translation. 4.4% increase in combined revenues of our megabrands, led by Corona, which g

Rimini Street and ServiceNow Partner with Apsen Farmacêutica to Deliver a Next-Generation Vision of Enterprise-Wide Workflow Automation7.5.2025 19:55:00 EEST | Press release

Knowledge 2025 —Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, management and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today at ServiceNow’s annual customer and partner event, Knowledge 2025, announced that Apsen Farmacêutica, a Brazilian pharmaceutical manufacturer, has partnered with Rimini Street and ServiceNow to implement a next-generation vision of enterprise-wide workflow automation. This new vision will enable autonomy across the company to help respond faster to market changes, reduce information silos and improve operational efficiency. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250507517040/en/ Rimini Street and ServiceNow Partner with Apsen Farmacêutica to Deliver a Next-Generation Vision of Enterprise-Wide Workflow Automation Apsen is prioritizing business needs above technology, leaning into a fl

Results from the VirTus Respiratory Research Ltd Human Rhinovirus Challenge Model Used to Advance Altesa BioSciences’ Lead Medicine into Advanced Clinical Trials7.5.2025 19:07:00 EEST | Press release

VirTus Respiratory Research Ltd, a leading respiratory-focused contract research organisation (CRO), today announced that results from their human rhinovirus challenge model in patients with chronic obstructive pulmonary disease (COPD) provided Altesa BioSciences with compelling evidence to advance their lead drug candidate, vapendavir, into large scale, late-stage clinical trials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250507489716/en/ Professor Sebastian Johnston https://www.prnewswire.com/news-releases/altesa-biosciences-details-positive-topline-vapendavir-results-from-phase-2-placebo-controlled-rhinovirus-challenge-study-in-copd-patients-302448650.html Rhinovirus infection is the cause of at least half of the acute respiratory deteriorations experienced by the millions of patients with chronic obstructive lung disease. “Before advancing vapendavir into clinical trials testing vapendavir on thousands of patients c

FlightSafety International Announces Major Expansion at Farnborough Airport7.5.2025 18:56:00 EEST | Press release

FlightSafety International (FSI), a global leader in aviation training, is pleased to announce the expansion of its facilities at Farnborough Airport, the home of British aviation and Europe’s leading airport for premium air travel connectivity, highlighting its commitment to enhancing aviation safety and training excellence in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250506583636/en/ Rendering: arriving at FlightSafety International The new FSI centre is expected to open in the second quarter of 2027. Lease terms have been finalised and the planning application was submitted in January. Construction is scheduled to start in late 2025 and finish by early 2027. FSI has operated a training centre at Farnborough Airport since 2004. The new facilities will boost training capacity by 40-50%, enabling more aviation professionals access to FSI's world-class training programmes. The current facility is 4,680 square met

Verimatrix Positioned as a Leader and Ace Performer in the 2025 SPARK Matrix TM for In-App Protection by QKS Group7.5.2025 18:45:00 EEST | Press release

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250507970501/en/ Verimatrix positioned as a Leader in the 2025 SPARK Matrix™ for In-App Protection by QKS Group. Verimatrix has been recognized for its comprehensive in-app protection capabilities, earning strong ratings across both Technology Excellence and Customer Impact in the latest SPARK Matrix™. The company has also been named an Ace Performer a recognition given to vendors that demonstrate revenue growth potential, partnership strategy, and customer acquisition—all evaluated over the last one-year period or since the previous SPARK Matrix assessment. The QKS Group SPARK Matrix™ provides competitive analysis & ranking of the leading In-App Protection vendors. For more information about Verimatrix, visit: https://www.verimatrix.com SPARK MatrixTM: In-App Protection, Q1 2025: https://qksgroup.com/market-research/spark-matrix-in-app-protection-q1-2025-8413 V

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye